Sapitinib

Drug Profile

Sapitinib

Alternative Names: AZD-8931

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; University College London
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Discontinued Advanced breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 23 Sep 2016 Sapitinib is still in phase I/II trials for Colorectal cancer (Combination therapy, Late-stage disease) in United Kingdom (PO) (NCT01862003)
  • 31 May 2014 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease) in United Kingdom (PO) (NCT01862003)
  • 31 Dec 2012 Discontinued - Phase-I for Gastric cancer in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top